Cervical Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Cervical Cancer, including details on symptoms, vaccine, screening, treatment, human papilloma virus (hpv), information.

Volume 2 (2005), Issue 3 (March)

1. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix.
   Eur J Cancer, 41(4): 523-30. [Abstract] [Full-text]
2. Differential effects of messages for breast and cervical cancer screening.
   J Health Care Poor Underserved, 16(1): 42-52. [Abstract] [Full-text]
3. Radiotherapy for uterine cervical cancer: results of the 1995-1997 patterns of care process survey in Japan.
   Jpn J Clin Oncol, 35(3): 139-48. [Abstract] [Full-text]
4. Cervical cancer-causing human papillomaviruses have an alternative initiation site for the L1 protein.
   Virus Genes, 30(1): 31-5. [Abstract] [Full-text]
5. Reflex high-risk human papillomavirus testing for women with atypical squamous cells of undetermined significance in cytologic smears: effects since implementation in a large clinical practice.
   Am J Clin Pathol, 123(4): 524-8. [Abstract] [Full-text]
6. Social inequities along the cervical cancer continuum: a structured review.
   Cancer Causes Control, 16(1): 63-70. [Abstract] [Full-text]
7. Plasma uric acid levels in women with cervical intraepithelial neoplasia.
   Nutr Cancer, 51(1): 25-31. [Abstract] [Full-text]
8. Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma.
   Hum Pathol, 36(2): 162-9. [Abstract] [Full-text]
9. Microglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells.
   Hum Pathol, 36(2): 154-61. [Abstract] [Full-text]
10. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer.
    Cancer Res, 65(5): 2018-25. [Abstract] [Full-text]
11. The role of human papillomavirus testing in cervical screening.
    J Clin Virol, 32: S34-42. [Abstract] [Full-text]
12. The epidemiology of human papillomavirus infections.
    J Clin Virol, 32: S16-24. [Abstract] [Full-text]
13. Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients.
    Int J Radiat Oncol Biol Phys, 61(4): 1078-86. [Abstract] [Full-text]
14. Radical radiotherapy for cervix cancer: the effect of waiting time on outcome.
    Int J Radiat Oncol Biol Phys, 61(4): 1071-7. [Abstract] [Full-text]
15. Feasibility of dose escalation using intensity-modulated radiotherapy in posthysterectomy cervical carcinoma.
    Int J Radiat Oncol Biol Phys, 61(4): 1062-70. [Abstract] [Full-text]
16. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival.
    Cancer, 103(6): 1258-64. [Abstract] [Full-text]
17. A DNA recombination-based approach to eliminate papillomavirus infection.
    Gene Ther, 12(6): 534-40. [Abstract] [Full-text]
18. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma.
    Br J Cancer, 92(5): 891-4. [Abstract] [Full-text]
19. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control.
    Vaccine, 23(17): 2388-94. [Abstract] [Full-text]
20. Leg coverage with towels during regional deep hyperthermia treatment and its effect on pelvic temperature and temperature distribution.
    Int J Hyperthermia, 21(1): 77-87. [Abstract] [Full-text]
21. Treatment with a belly-board device significantly reduces the volume of small bowel irradiated and results in low acute toxicity in adjuvant radiotherapy for gynecologic cancer: results of a prospective study.
    Radiother Oncol, 74(3): 267-74. [Abstract] [Full-text]
22. A randomised comparison of two brachytherapy devices for the treatment of uterine cervical carcinoma.
    Radiother Oncol, 74(3): 247-50. [Abstract] [Full-text]
23. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.
    Radiother Oncol, 74(3): 235-45. [Abstract] [Full-text]
24. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening.
    Cancer Epidemiol Biomarkers Prev, 14(3): 677-86. [Abstract] [Full-text]
25. cDNA array analysis of cytobrush-collected normal and malignant cervical epithelial cells: a feasibility study.
    Cancer Genet Cytogenet, 158(1): 35-42. [Abstract] [Full-text]
26. The role of viral integration in the development of cervical cancer.
    Cancer Genet Cytogenet, 158(1): 27-34. [Abstract] [Full-text]
27. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
    Eur J Health Econ, 6(1): 30-7. [Abstract] [Full-text]
28. HIV and cancer of the cervix.
    Best Pract Res Clin Obstet Gynaecol, 19(2): 269-76. [Abstract] [Full-text]
29. Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma.
    Int J Gynaecol Obstet, 89(1): 39-44. [Abstract] [Full-text]
30. A comparative study of two methods of large loop excision of the transformation zone.
    BJOG, 112(4): 490-4. [Abstract] [Full-text]
31. Fine mapping and evaluation of candidate genes for cervical cancer on 11q23.
    Genes Chromosomes Cancer, 43(1): 95-103. [Abstract] [Full-text]
32. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
    Int J Cancer, 114(6): 973-6. [Abstract] [Full-text]
33. Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study.
    Mod Pathol, 18(4): 528-34. [Abstract] [Full-text]
34. HPV16, HPV18, and HIV infection may influence cervical cytokine intralesional levels.
    Virology, 334(2): 294-8. [Abstract] [Full-text]
35. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up.
    Br J Cancer, 92(6): 990-4. [Abstract] [Full-text]
36. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results.
    JAMA, 293(12): 1471-6. [Abstract] [Full-text]
37. Defining and measuring reproductive concerns of female cancer survivors.
    J Natl Cancer Inst Monogr. [Abstract] [Full-text]
38. Fertility-sparing surgery for malignancies in women.
    J Natl Cancer Inst Monogr. [Abstract] [Full-text]
39. Screening for breast and cervical cancer in a large German city: participation, motivation and knowledge of risk factors.
    Eur J Public Health, 15(1): 70-7. [Abstract] [Full-text]
40. P-cadherin expression in glandular lesions of the uterine cervix detected by liquid-based cytology.
    Cytopathology, 16(2): 88-93. [Abstract] [Full-text]
41. Laboratory performance measures: evidence against low-risk women explaining low detection rates of high-grade abnormalities.
    Cytopathology, 16(2): 77-81. [Abstract] [Full-text]
42. Parallel nanoliter detection of cancer markers using polymer microchips.
    Lab Chip, 5(4): 416-20. [Abstract] [Full-text]
43. Pediatric radical abdominal trachelectomy for cervical clear cell carcinoma: a novel surgical approach.
    Gynecol Oncol, 97(1): 296-300. [Abstract] [Full-text]
44. Umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer: a true port-site metastasis?
    Gynecol Oncol, 97(1): 292-5. [Abstract] [Full-text]
45. Neoadjuvant combined chemotherapy followed by external whole pelvic irradiation in two cases of primary extranodal non-Hodgkin's lymphoma of the uterine cervix.
    Gynecol Oncol, 97(1): 285-7. [Abstract] [Full-text]
46. Single vaginal ectopic ureter of fetal metanephric duct origin, ipsilateral kidney agenesis, and ipsilateral rudimentary uterine horn of the bicornuate uterus.
    Gynecol Oncol, 97(1): 276-8. [Abstract] [Full-text]
47. Post-transplant lymphoproliferative disorder of the cervix.
    Gynecol Oncol, 97(1): 271-5. [Abstract] [Full-text]
48. A case of invasive squamous cell carcinoma on the surface of pedunculated cervical leiomyoma presenting an exophytic cervical cancer.
    Gynecol Oncol, 97(1): 253-5. [Abstract] [Full-text]
49. Sigmoid impaction secondary to urinary stones: case report and review of literature.
    Gynecol Oncol, 97(1): 234-7. [Abstract] [Full-text]
50. Primary stage I-IIE non-Hodgkin's lymphoma of uterine cervix and upper vagina: evidence for a conservative approach in a study on three patients.
    Gynecol Oncol, 97(1): 214-8. [Abstract] [Full-text]
51. Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers.
    Gynecol Oncol, 97(1): 206-13. [Abstract] [Full-text]
52. FDG-PET for management of cervical and ovarian cancer.
    Gynecol Oncol, 97(1): 183-91. [Abstract] [Full-text]
53. Sensitization of cervical cancer cell lines to low-dose radiation by retinoic acid does not require functional p53.
    Gynecol Oncol, 97(1): 142-50. [Abstract] [Full-text]
54. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Gynecol Oncol, 97(1): 126-35. [Abstract] [Full-text]
55. Acute diarrhea during pelvic irradiation: is small-bowel volume effect different in gynecologic patients with prior abdomen operation or not?
    Gynecol Oncol, 97(1): 118-25. [Abstract] [Full-text]
56. The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma.
    Gynecol Oncol, 97(1): 96-103. [Abstract] [Full-text]
57. Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia.
    Gynecol Oncol, 97(1): 53-9. [Abstract] [Full-text]
58. Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies.
    Gynecol Oncol, 97(1): 35-40. [Abstract] [Full-text]
59. Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women.
    J Med Virol, 76(1): 106-10. [Abstract] [Full-text]
60. Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women.
    Int J Cancer, 115(1): 114-20. [Abstract] [Full-text]
61. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India.
    Bull World Health Organ, 83(3): 186-94. [Abstract] [Full-text]
62. Prevalence of human Papilloma Virus in HIV-positive and HIV-negative patients in the State of Bahia: a pilot study.
    Braz J Infect Dis, 8(5): 356-62. [Abstract] [Full-text]
63. VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix.
    Cancer Lett, 221(1): 105-18. [Abstract] [Full-text]
64. Effects of 3-methylcholanthrene on the transcriptional activity and mRNA accumulation of the oncogene hWAPL.
    Cancer Lett, 221(1): 21-8. [Abstract] [Full-text]
65. Adenoviral p53 effects and cell-specific E7 protein-protein interactions of human cervical cancer cells.
    Biosens Bioelectron, 20(11): 2236-43. [Abstract] [Full-text]
66. Mexican physicians' knowledge and attitudes about the human papillomavirus and cervical cancer: a national survey.
    Sex Transm Infect, 81(2): 135-41. [Abstract] [Full-text]
67. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands.
    Int J Cancer, 115(2): 268-75. [Abstract] [Full-text]
68. A randomised public-health trial on automation-assisted screening for cervical cancer in Finland: performance with 470,000 invitations.
    Int J Cancer, 115(2): 307-11. [Abstract] [Full-text]

© 2004-2008 Cervical Cancer Research Today. All Rights Reserved.